WHO ICTRP trial
Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant…
JPRN-UMIN000016998 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000016998 |
|---|---|
| Public title | Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant polycystic kidney disease |
| Scientific title | Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant polycystic kidney disease - GLSG ADPKD |
| Primary sponsor | Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Observational |
| Phase | Not selected |
| Countries | Japan |
| Conditions | ADPKD |
| Registration date | Jan 1, 2020 |
| Target size | 5 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: